Search Results for: PIK3CA

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CSF1R colony stimulating factor 1 receptor
  • Other interleukin signaling
  • Transcriptional Regulation by VENTX
  • Imatinib
  • Sunitinib
  • ABT-869
  • 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE
  • 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE
  • Fostamatinib
  • Erdafitinib
  • Pexidartinib
  • Choriocarcinoma
DDX5 DEAD-box helicase 5
  • SUMOylation of transcription cofactors
  • mRNA Splicing - Major Pathway
  • Estrogen-dependent gene expression
  • Replication of the SARS-CoV-1 genome
  • Replication of the SARS-CoV-2 genome
  • Artenimol
  • Prostate cancer
FANCC FA complementation group C
  • Fanconi Anemia Pathway
  • TP53 Regulates Transcription of DNA Repair Genes
  • Fanconi anemia
FASLG Fas ligand
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • Interleukin-4 and Interleukin-13 signaling
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • FOXO-mediated transcription of cell death genes
  • TNFs bind their physiological receptors
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FTL ferritin light chain
  • Scavenging by Class A Receptors
  • Golgi Associated Vesicle Biogenesis
  • Neutrophil degranulation
  • Iron uptake and transport
  • Iron Dextran
  • Protoporphyrin
  • Ferric pyrophosphate
  • Sodium ferric gluconate complex
  • Ferric pyrophosphate citrate
  • Neurodegeneration with brain iron accumulation (NBIA); Hallervorden-Spatz syndrome; Neuroferritinopathy; Aceruloplasminemia
GLIS2 GLIS family zinc finger 2
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
MAP2K1 mitogen-activated protein kinase kinase 1
  • MAPK3 (ERK1) activation
  • Frs2-mediated activation
  • Signal transduction by L1
  • Uptake and function of anthrax toxins
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • K-252a
  • 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
  • Cobimetinib
  • Bosutinib
  • (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
  • 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
  • PD-0325901
  • N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
  • 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
  • Trametinib
  • Selumetinib
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
PDGFRA platelet derived growth factor receptor alpha
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Imatinib-resistant PDGFR mutants
  • Sunitinib-resistant PDGFR mutants
  • Regorafenib-resistant PDGFR mutants
  • Sorafenib-resistant PDGFR mutants
  • PDGFR mutants bind TKIs
  • Becaplermin
  • Imatinib
  • Sunitinib
  • XL820
  • Olaratumab
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Ripretinib
  • Glioma
PDGFRB platelet derived growth factor receptor beta
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Becaplermin
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • XL999
  • XL820
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Nintedanib
  • Polaprezinc
  • Trapidil
  • Foreskin fibroblast (neonatal)
  • Fostamatinib
  • Erdafitinib
  • Pexidartinib
  • Ripretinib
  • Pralsetinib
  • Glioma
SMAD2 SMAD family member 2
  • Signaling by NODAL
  • Signaling by NODAL
  • Signaling by Activin
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Transcriptional regulation of pluripotent stem cells
  • Ub-specific processing proteases
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Dexfosfoserine
  • Colorectal cancer
SQSTM1 sequestosome 1
  • NRIF signals cell death from the nucleus
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • PINK1-PRKN Mediated Mitophagy
  • Interleukin-1 signaling
  • Pexophagy
  • Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
UMPS uridine monophosphate synthetase
  • Pyrimidine biosynthesis
  • 6-hydroxyuridine-5'-phosphate
  • Orotic aciduria
ADAP1 ArfGAP with dual PH domains 1
  • Nuclear signaling by ERBB4
AMBP alpha-1-microglobulin/bikunin precursor
  • Scavenging of heme from plasma
APLP2 amyloid beta precursor like protein 2
  • Platelet degranulation
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
  • Zinc
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
APPL1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1
  • Caspase activation via Dependence Receptors in the absence of ligand
ATP5IF1 ATP synthase inhibitory factor subunit 1
BEX1 brain expressed X-linked 1
BEX2 brain expressed X-linked 2

Page 2 out of 4 pages